Orally dissolvable peptide films and associated methods
Orally dissolvable films for GHK-Cu delivery address the limitations of existing administration forms by offering non-invasive systemic delivery, improving wound healing and anti-inflammatory effects.
Patent Information
- Application Number
- PCT/US2026/028307
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-14
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Existing administration forms of Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu), such as injectable and topical formulations, have limitations and drawbacks, particularly in providing non-invasive systemic delivery.
Orally dissolvable peptide films, such as those containing GHK-Cu, are developed for buccal or sublingual delivery, utilizing carriers like pullulan and film-forming substances, to facilitate non-invasive systemic administration.
The orally dissolvable films provide effective systemic delivery of GHK-Cu, enhancing wound healing, collagen synthesis, anti-inflammatory effects, and other therapeutic benefits without invasive methods.
Smart Images

Figure IMGF000004_0001 
Figure IMGF000021_0001_TABLE 
Figure IMGF000022_0001_TABLE
Abstract
Description
[0001] Thorpe North & Western, LLP DocketNo.: 5016-005. PCT
[0002] ORALLY DISSOLVABLE PEPTIDE FILMS AND ASSOCIATED METHODS
[0003] PRIORITY DATA
[0004] This application claims the benefit of United States Provisional Patent Application Serial No. 63 / 805,881, filed on May 14, 2025, which is incorporated herein by reference.
[0005] TECHNOLOGY FIELD
[0006] The present disclosure involves therapeutic formulations containing peptides, including tripeptides, and tripeptide complexes, such as Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu), and related compounds, as well as methods of using and manufacturing such formulations. Accordingly, this disclosure involves the fields of chemistry and health science.
[0007] BACKGROUND
[0008] Various peptides have been identified and considered for therapeutic uses. One such peptide, Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu), is a tripeptide composed of 3 amino acids that has a strong affinity for copper, which results in binding with copper (II). The human body naturally produces GHK-Cu in small amounts in the plasma, and can also be found in saliva and urine. GHK-Cu can modulate expression of a large number of human genes, generally reversing gene expression to a healthier state. As a result, GHK-Cu has the potential in medicine to act as an effective systemic healing agent.
[0009] DESCRIPTION OF EMBODIMENTS
[0010] Although the following detailed description contains many specifics for the purpose of illustration, a person of ordinary skill in the art will appreciate that many variations and alterations to the following details can be made and are considered to be included herein. Accordingly, the following embodiments are set forth without any loss of generality to, and without imposing limitations upon, any claims set forth. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0011] Thorpe North & Western, LLP
[0012] DocketNo.: 5016-005. PCT
[0013] As used in this written description, the singular forms “a,” “an” and “the” provide express support for plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a particle” includes a plurality of particles.
[0014] In this application, “comprises,” “comprising,” “containing” and “having” and the like can have the meaning ascribed to them in U. S. Patent law and can mean “includes,” “including,” and the like, and are generally interpreted to be open ended terms. The terms “consisting of’ or “consists of’ are closed terms, and include only the components, structures, steps, or the like specifically listed in conjunction with such terms, as well as that which is in accordance with U. S. Patent law. “Consisting essentially of’ or “consists essentially of' have the meaning generally ascribed to them by U. S. Patent law. In particular, such terms are generally closed terms, with the exception of allowing inclusion of additional items, materials, components, steps, or elements, that do not materially affect the basic and novel characteristics or function of the item(s) used in connection therewith. For example, trace elements present in a composition, but not affecting the compositions nature or characteristics would be permissible if present under the “consisting essentially of’ language, even though not expressly recited in a list of items following such terminology. When using an open-ended term, like “comprising” or “including,” in this written description it is understood that direct support should be afforded also to “consisting essentially of’ language as well as “consisting of' language as if stated explicitly and vice versa.
[0015] The terms “first,” “second,” “third,” “fourth,” and the like in the description and in the claims, if any, are used for distinguishing between similar elements and not necessarily for describing a particular sequential or chronological order. It is to be understood that any terms so used are interchangeable under appropriate circumstances such that the embodiments described herein are, for example, capable of operation in sequences other than those illustrated or otherwise described herein. Similarly, if a method is described herein as comprising a series of steps, the order of such steps as presented herein is not necessarily the only order in which such steps may be performed, and certain of the stated steps may possibly be omitted and / or certain other steps not described herein may possibly be added to the method.
[0016] Occurrences of the phrase “in one embodiment,” or “in one aspect,” herein do not necessarily all refer to the same embodiment or aspect.
[0017] As used herein, “subject” refers to a mammal that may benefit from GHK-Cu therapy. In one aspect the mammal may be a human.
[0018] Thorpe North & Western, LLP
[0019] DocketNo.: 5016-005. PCT
[0020] As used herein, the terms “treat,” “treatment,” or “treating” when used in conjunction with the administration of a GHK metal complex, such as GHK-Cu, including compositions and dosage forms thereof, refers to administration to subjects who are either asymptomatic or symptomatic. In other words, “treat,” “treatment,” or “treating” can be to reduce, ameliorate or eliminate symptoms associated with a condition present in a subject, or can be prophylactic, (i.e. to prevent or reduce the occurrence of the symptoms in a subject). Such prophylactic treatment can also be referred to as prevention of the condition.
[0021] As used herein, the terms “formulation” and “composition” are used interchangeably and refer to a mixture of two or more compounds, elements, or molecules. In some aspects the terms “formulation” and “composition” may be used to refer to a mixture of one or more active agents with a carrier or other excipients. Compositions can take nearly any physical state, including solid, liquid (i.e. solution), or gas. Furthermore, the term “dosage form” can include one or more formulation(s) or composition(s) provided in a format for administration to a subject. In one example, a composition can be a solution that releases nitric oxide.
[0022] As used herein the terms “therapeutic agent,” “active agent,” “pharmaceutical agent,” “drug,” and the like can be used interchangeably and refer to an agent that can have a beneficial or positive effect (e.g. a medicinal, nutritional, restorative, or other wellnessimparting or positive health benefit imparting effect) on a subject when administered to the subject in an appropriate or effective amount. In some embodiments, GHK-Cu can be an active agent.
[0023] A "primary active agent,” refers to a therapeutic agent or active agent (e.g. compound, molecule, or material) in a composition that contains the highest degree of activity or potency, especially toward an indication for which the composition is indicated. In some embodiments, a primary active agent in a composition may be the active agent in the highest dose or greatest concentration / amount. In some embodiments, GHK-Cu can be a primary active agent.
[0024] The terms “additional active agent,” “supplemental active agent,” “secondary active agent,” and the like can be used interchangeably and refer to a compound, molecule, or material other than the primary active agent that has beneficial physiologic activity when administered to a subj ect in an effective amount. A secondary active agent can be active against the same or similar indication as a primary active agent and have the same or a similar mechanism of action. In this regard, a secondary active agent can reinforce or otherwise compliment the primary active agent. Alternatively, a secondary active agentThorpe North & Western, LLP DocketNo.: 5016-005. PCT can have therapeutic activity against a different, (including different, but related) indication as the primary active agent and can have a different mechanism of action. In some embodiments, primary and secondary active agents can work together to provide an overall synergistic physiological effect. Exemplary additional active agents can include without limitation, peptides, hormones, vitamins, etc.
[0025] As used herein. “GHK-Cu” refers to Glycyl-L-Histidyl-L-Lysine Copper, which is a 3 amino acid tripeptide complexed or bound to a copper (II). GHK-Cu generally has the amino acid sequence Gly-His-Lys. GHK-Cu typically has the chemical formula C14H24CuN6O4 and a molecular weight of 403.92 g / mol. The general chemical structure
[0026]
[0027] GHK-Cu is a naturally occurring peptide produced in the body and is thought to have a number of therapeutic benefits, such as in promoting wound healing, reducing inflammation, acting as an antioxidant, muscle recovery, and promoting blood vessel growth among others.
[0028] As used herein, “GHK-Cu compounds” refers not only to GHK-Cu itself, but also to closely related compounds, including without limitation, analogs, salts, esters, isomers, prodrugs, metabolites, or other functional derivatives thereof that exert a therapeutic effect substantially similar to, or better than. GHK-Cu when administered to a subject in a therapeutically effective amount.
[0029] As used herein “GHK-Cu like compounds” refers to tripeptides complexed or bound to copper or other metals and closely related compounds, including without
[0030] Thorpe North & Western, LLP DocketNo.: 5016-005. PCT limitation, analogs, salts, esters, isomers, prodrugs, metabolites, or other functional derivatives that exert a therapeutic effect via a combination of mechanisms of action, substantially similar to the mechanisms of action exerted by GHK-Cu when administered to a subject in a therapeutically effective amount.
[0031] It is to be understood that as used in this written description, the recitation of one of the terms “GHK-Cu”, ‘“GHK-Cu compounds,” or ‘“GHK-Cu like compounds” provide express support for one another as if each term were individually used.
[0032] As used herein, an “‘effective amount” of an agent is an amount sufficient to accomplish a specified task or function desired of the agent. A “therapeutically effective amount” of a composition, drug, or agent refers to a non-toxic, but sufficient amount of the composition, drug, or agent, to achieve therapeutic results in treating or preventing a condition for which the composition, drug, or agent is known to be effective. It is understood that various biological factors may affect the ability' of a substance to perform its intended task. Therefore, an “effective amount” or a “therapeutically effective amount” may be dependent in some instances on such biological factors. Further, while the achievement of therapeutic effects may be measured by physician, veterinarian, or other qualified medical personnel, using evaluations known in the art, it is recognized that individual variation and response to treatments may make the achievement of therapeutic effects a somewhat subjective decision. The determination of an effective amount or therapeutically effective amount is well within the ordinary skill in the art of pharmaceutical sciences and medicine. See, for example, Meiner and Tonascia, “‘Clinical Trials: Design, Conduct, and Analysis,” Monographs in Epidemiology and Biostatistics, Vol. 8 (1986).
[0033] As used herein, the terms “release” refers to the discharge or liberation of an active agent or other substance from a composition, or dosage form and “release rate” refers to the rate at which the active agent or substance is discharged or liberated. In one example, a therapeutic agent or substance may be released in vitro. In another aspect, the therapeutic agent or substance may be released in vivo.
[0034] As used herein, comparative terms such as “increased,” “decreased,” “better,” “worse,” “‘higher,” “lower,” “‘enhanced,” “maximized,” “minimized,” and the like refer to a property of a device, component, composition, or activity that is measurably different from other devices, components, compositions or activities that are in a surrounding or adjacent area, that are similarly situated, that are in a single device or composition or inThorpe North & Western, LLP
[0035] DocketNo.: 5016-005. PCT multiple comparable devices or compositions, that are in a group or class, that are in multiple groups or classes, or as compared to the known state of the art.
[0036] As used herein, the term '‘substantially” refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result. For example, an object that is “substantially” enclosed would mean that the object is either completely enclosed or nearly completely enclosed. The exact allowable degree of deviation from absolute completeness may in some cases depend on the specific context. However, generally speaking the nearness of completion will be so as to have the same overall result as if absolute and total completion were obtained. The use of “substantially” is equally applicable when used in a negative connotation to refer to the complete or near complete lack of an action, characteristic, property, state, structure, item, or result. For example, a composition that is '‘substantially free of’ particles would either completely lack particles, or so nearly completely lack particles that the effect would be the same as if it completely lacked particles. In other words, a composition that is “substantially free of’ an ingredient or element may still actually contain such item as long as there is no measurable effect thereof. It is to be understood that in this written desenption, instances where the term '‘substantially” is used in connection with a given item (e g. element, process, result, characteristic, etc.) also provide express support for the item as though the term “substantially” did not appear, and vice versa.
[0037] As used herein, the term “about” is used to provide flexibility to a numerical range endpoint by providing that a given value may be “a little above” or “a little below” the endpoint. Unless otherwise stated, use of the term “about” in accordance with a specific number or numerical range should also be understood to provide support for such numerical terms or range without the term “about”. For example, for the sake of convenience and brevity, a numerical range of “about 50 ml to about 80 ml” should also be understood to provide support for the range of “50 ml to 80 ml.” Furthermore, it is to be understood that in this specification support for actual numerical values is provided even when the term “about” is used therewith. For example, the recitation of “about” 30 should be construed as not only providing support for values a little above and a little below 30, but also for the actual numerical value of 30 as well.
[0038] As used herein, a plurality of items, structural elements, compositional elements, and / or materials may be presented in a common list for convenience. However, these lists should be constmed as though each member of the list is individually identified as a separate and unique member. Thus, no individual member of such list should be construedThorpe North & Western, LLP
[0039] DocketNo.: 5016-005. PCT as a de facto equivalent of any other member of the same list solely based on their presentation in a common group without indications to the contrary.
[0040] Concentrations, amounts, and other numerical data may be expressed or presented herein in a range format. It is to be understood that such a range format is used merely for convenience and brevity and thus should be interpreted flexibly to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. As an illustration, a numerical range of “about 1 to about 5” should be interpreted to include not only the explicitly recited values of about 1 to about 5, but also include individual values and sub-ranges within the indicated range. Thus, included in this numerical range are individual values such as 2, 3, and 4 and sub-ranges such as from 1-3, from 2-4, and from 3-5, etc., as well as 1, 2, 3, 4, and 5, individually, and further including decimal or fraction values such as 1.8, 2.3, 3.7, and 4.2.
[0041] This same principle applies to ranges reciting only one numerical value as a minimum or a maximum. Furthermore, such an interpretation should apply regardless of the breadth of the range or the characteristics being described.
[0042] Reference throughout this specification to “an example” means that a particular feature, structure, or characteristic described in connection with the example is included in at least one embodiment. Thus, appearances of the phrases “in an example” in various places throughout this specification are not necessarily all referring to the same embodiment.
[0043] Reference in this specification may be made to devices, structures, systems, or methods that provide “improved” performance. It is to be understood that unless otherwise stated, such “improvement” is a measure of a benefit obtained based on a comparison to devices, structures, systems or methods in the prior art. Furthermore, it is to be understood that the degree of improved performance may vary between disclosed embodiments and that no equality or consistency in the amount, degree, or realization of improved performance is to be assumed as universally applicable.
[0044] Example Embodiments
[0045] An initial overview of invention embodiments is provided below and specific embodiments are then described in further detail. This initial summaiy is intended to aid readers in understanding the technological concepts more quickly, but is not intended toThorpe North & Western, LLP DocketNo.: 5016-005. PCT identify key or essential features thereof, nor is it intended to limit the scope of the claimed subject matter.
[0046] As described above, Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu) has the potential in medicine to act as an effective systemic healing agent. GHK-Cu has a significant impact on various cells due to its stem cell-like properties, including without limitation, skin fibroblasts, stimulation of collagen, and inflammation. It also can have a profound effect on wound healing and the attraction of immune cells, as well as having an effect on the promotion of blood vessel growth. Additionally, GHK-Cu can have cosmetic benefits. GHK-Cu is widely used for anti-aging, preventing wrinkles and firming the skin.
[0047] A number of mechanisms of action have been hypothesized or identified for GHK-Cu in achieving the foregoing benefits or therapeutic effects. For example:
[0048] Medical Applications
[0049] Wound Healing: GHK-Cu strongly enhances and / or accelerates healing parameters, such as angiogenesis and wound closure (healing) including in both wound chambers and full thickness wounds including without limitation, bums and ulcers.
[0050] Collagen Synthesis: GHK-Cu stimulates the production of collagen, a key structural protein in connective tissues. This is particularly beneficial for healing tendons, ligaments, and skin, which compliments the wound healing effects of GHK-Cu.
[0051] Anti-Inflammatory Effects: GHK-Cu reduces oxidative stress and inhibits or down- regulates expression of pro-inflammatory genes and impacts the production of various cytokines. It also upregulates expression of anti-inflammatory genes and impacts production of related cytokines and other proteins. This helps in protecting tissues from damage and promoting recovery.
[0052] Suppression of Fibrinogen: GHK-Cu can suppress fibrinogen, which forms blood clots. By suppressing the production of Interleukin-6, a main positive regulator of fibrinogen production, GHK-Cu has a general inhibitory effect on fibrinogen synthesis.
[0053] Anti-Cancer Effects: GHK-Cu can upregulate the expression of ten caspase and caspase-associated genes, as well as positively affecting 84 genes associated with DNA repair and other anti-cancer effects.
[0054] Antioxidant and DNA Repair: GHK-Cu can be used to protect against oxidative damage, support DNA repair, and reverse cellular aging markers.
[0055] Thorpe North & Western, LLP DocketNo.: 5016-005. PCT
[0056] Lung and Organ Regeneration: GHK-Cu plays a role in lung tissue repair and anti- fibrotic activity, showing potential in conditions like COPD or pulmonary’ fibrosis.
[0057] Neuroprotection: GHK-Cu promote nerve regeneration and protect against neurodegenerative changes, having therapeutic relevance in brain injury’ and cognitive decline.
[0058] Cosmetic Applications
[0059] Skin Rejuvenation: GHK-Cu stimulates the production of collagen, elastin, and other ECM components, improving skin firmness, elasticity’, and hydration.
[0060] Anti-Aging: It reduces fine lines, wrinkles, and photodamage by enhancing skin regeneration and modulating genes associated with youthfulness.
[0061] Hair Growth: GHK-Cu promotes hair follicle enlargement and angiogenesis around follicles, supporting hair regrowth in androgenic alopecia and thinning.
[0062] Skin Repair After Procedures: Used post-microneedling, laser treatments, and chemical peels to speed recovery and enhance outcomes.
[0063] One indication for which GHK-Cu shows particular promise is in treating male pattern baldness (androgenetic alopecia). In particular, GHK-Cu therapy stimulates hair follicle growth in part by increasing the size of hair follicles and extending the anagen (growth) phase of the hair cycle, which is typically shortened in male pattern baldness. Additionally, GHK-Cu improves blood flow to the scalp through angiogenesis around follicles which enhances oxygen and nutrient delivery’. Moreover, GHK-Cu reduces inflammation, including chronic inflammation in the scalp. Chronic scalp inflammation can exacerbate hair loss. GHK-Cu helps downregulate pro-inflammatory cytokines and promotes a healthier follicular environment. Yet further, GHK-Cu protects against DHT-induced damage. While GHK-Cu doesn’t directly block DHT (the main hormone driving male pattern baldness), it may help mitigate the damage DHT causes to hair follicles through its regenerative and anti-inflammatory’ actions. Additionally, GHK-Cu enhances scalp healing by supporting tissue repair and faster recovery, enhancing results when paired with other regenerative procedures.
[0064] While GHK-Cu has been administered as injectable formulations and topical / transdermal formulations, a number of limitations and drawback exist with these administration forms. The present inventors have discovered that oral transmucosal delivery, including buccal and sublingual delivery through the mucosa of the oral cavityThorpe North & Western, LLP
[0065] DocketNo.: 5016-005. PCT
[0066] (e.g. oral mucosa) present particular promise and expanded opportunity for non-invasive systemic administration.
[0067] It is noted that when discussing the GHK-Cu compositions and methods described herein, these relative discussions can be considered applicable to the other examples, whether or not they are explicitly discussed in the context of that example. Thus, for example, in discussing an active agent in a particular composition, such disclosure is also relevant to and directly supported in the context of the methods of administration, methods of treatment, and methods of manufacture described herein, and vice versa.
[0068] In one embodiment, a composition can include an orally-dissolvable carrier having a therapeutically effective amount of an active agent. In some embodiments, the active agent can be a peptide composed of three to five amino acids bound to a metal ion. In some examples, the active agent can be GHK-Cu. Generally, GHK-Cu can be present in the composition an amount from about 0.5 wt% to about 40 wt% based on the total dry weight of the composition. In other examples, GHK-Cu can be present in the composition in an amount from about 1 wt% to about 35 wt%, from about 1 wt% to about 10 wt%, from about 5 wt% to about 25 wt%, from about 3 wt% to about 40 wt%, or from about 2 wt% to about 35 wt% of the total dry weight of the composition. In some additional examples, GHK-Cu can be present in the composition in an amount from about 0.1 mg to about 10 mg. In other examples, GHK-Cu can be present in the composition in an amount from about 0.5 mg to about 6 mg, from about from about 0.5 mg to about 1.5 mg. from about 1 mg to about 2 mg, from about 1.2 mg to about 1.75 mg, or from about 0.7 mg to about 2 mg. In one specific example, GHK-Cu can be present in the composition in an amount from about 0.75 mg to about 1.75 mg. In one example, the GHK-CU can be present in the composition in an amount of about 3 mg.
[0069] The orally-dissolvable carrier can be a tablet, wafer, troche, film, or lozenge. In some specific examples, the orally-dissolvable carrier can be an orally-dissolvable film, which can include a variety' of film forming substances. In one example, the orally-dissolvable film can include pullulan, which is a fibrous polymer derived from a type of black yeast. Pullulan is highly soluble, making it a good choice for an orally-dissolvable film. In addition, pullulan is tasteless, odorless, edible, and biodegradable while being non-carcinogenic, non-toxic, non-immunogenic, and non-mutagenic. Examples of other film forming agents or substances include without limitation, sodium alginate, HPMC E3 or E5 or E15, CMC, polyvinylpyrollidone, pectin or gelatin, and combinations thereof. The film forming substance used to make the orally-dissolvable film can be present in the
[0070] Thorpe North & Western, LLP
[0071] DocketNo.: 5016-005. PCT composition in an amount from about 40 wt% to about 65 wt% based on the total dry weight of the composition. In other examples, the film forming substance can be present in the composition in an amount from about 40 wt% to about 50 wt%, from about 45 wt% to about 55 wt%, from about 48 wt% to about 60 wt%, or from about 45 wt% to about 65 wt% of the total dry weight of the composition. In some specific examples, the film forming substance can be present in the composition in an amount of from about 53 wt% to about 58 wt% of the total dry weight of the composition. In some additional examples, the film forming substance can be present in the composition in an amount from about 45 mg to about 85 mg. In other examples, the film forming substance can be present in the composition in an amount from about 45 mg to about 60 mg, from about from about 42 mg to about 70 mg, from about 50 mg to about 75 mg. from about 52 mg to about 65 mg, or from about 60 mg to about 85 mg. In some specific examples, the film forming substance can be present in the composition in an amount from about 65 mg to about 70 mg.
[0072] In some examples, the composition can additionally include a cyclodextrin. Cyclodextrin can be used as a penetration enhancer, solubilizer, or a flavor ingredient. A variety of cyclodextrins can be used, including alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin, alpha-cyclodextrin derivatives, beta-cyclodextrin derivatives, gamma-cyclodextrin derivatives, or combinations thereof. In some specific examples, hydroxypropyl beta-cyclodextrin can be used. Varying amounts of cyclodextrin can be included in the composition. Generally, cyclodextrin can be present in the composition in an amount from about 1 wt% to about 35 wt%, from about 1 wt% to about 10 wt%, from about 5 wt% to about 25 wt%, from about 3 wt% to about 40 wt%, or from about 2 wt% to about 35 wt% of the total dry weight of the composition. In some additional examples, cyclodextrin can be present in the composition in an amount from about 0.1 mg to about 2 mg. In other examples, cyclodextrin can be present in the composition in an amount from about 0.5 mg to about 0.8 mg, from about from about 0.5 mg to about 1 mg, from about 0.3 mg to about 0.8 mg, from about 0.5 mg to about 1.5 mg, or from about 0.2 mg to about 1.7 mg. In some specific examples, cyclodextrin can be present in an amount from about 0.5 mg to about 1.5 mg. In further examples, the composition can additionally include or exclude optional ingredients. Optional ingredients can include or exclude at least one of a stabilizer, sweetener, saliva stimulator, plasticizer, coloring agent, flavor modifier, thickening agent, emulsifier, penetration enhancer, or gumming agent.
[0073] A non-limiting list of stabilizers which may be used include without limitation, hydroxypropyl methylcellulose, carboxymethyl cellulose, pectin, xanthan gum, arabicaThorpe North & Western, LLP
[0074] DocketNo.: 5016-005. PCT gum or lecithin, or combinations thereof. Stabilizers can be present in the composition in an amount from about 0.5 wt% to about 10 wt% based on the total dry weight of the composition. In other examples, stabilizers can be present in the composition in an amount from about 1 wt% to about 10 wt%, from about 5 wt% to about 8 wt%, from about 0.5 wt% to about 5 wt%, or from about 2 wt% to about 10 wt% of the total dry weight of the composition. In some additional examples, stabilizers can be present in the composition in an amount from about 2 mg to about 15 mg. In other examples, stabilizers can be present in the composition in an amount from about 2 mg to about 5 mg, from about from about 5 mg to about 10 mg, from about 5 mg to about 15 mg, from about 2 mg to about 8 mg, or from about 10 mg to about 15 mg. In some specific examples, stabilizers can be present in an amount from about 7 mg to about 9 mg.
[0075] Compositions presented herein may also include a sweetener. A non-limiting list of sweeteners which can be included in the composition can include stevia, aspartame, sucralose, acesulfame potassium, saccharin, luo han guo, erythritol, xylitol, or combinations thereof. Sweeteners can be present in the composition in an amount from about 0.5 wt% to about 12 wt% based on the total dry weight of the composition. In other examples, sweeteners can be present in the composition in an amount from about 1 wt% to about 10 wt%, from about 5 wt% to about 8 wt%, from about 0.5 wt% to about 5 wt%, or from about 2 wt% to about 12 wt% of the total dry weight of the composition. In some specific examples, sweeteners can be present in an amount from about 1.2 wt% to about 6 wt% of the total dry weight of the composition. In some additional examples, sweeteners can be present in the composition in an amount from about 3 mg to about 12 mg. In other examples, sweeteners can be present in the composition in an amount from about 3 mg to about 5 mg, from about from about 5 mg to about 10 mg, from about 5 mg to about 12 mg, from about 2 mg to about 8 mg, or from about 10 mg to about 12 mg. In some specific examples, sweeteners can be present in an amount from about 6 mg to about 8 mg.
[0076] Compositions presented herein may also include a saliva stimulator. A non-limiting list of saliva stimulators which can be included in the composition can include citric acid, malic acid, tartaric acid, or combinations thereof. Saliva stimulators can be present in the composition in an amount from about 0.5 wt% to about 5 wt% based on the total dry weight of the composition. In other examples, saliva stimulators can be present in the composition in an amount from about 1 wt% to about 5 wt%, from about 2 wt% to about 4 wt%, from about 0.5 wt% to about 2.5 wt%. or from about 1 wt% to about 3 wt% of the total dry weight of the composition. In some additional examples, saliva stimulators can be presentThorpe North & Western, LLP
[0077] DocketNo.: 5016-005. PCT in the composition in an amount from about 1 mg to about 5 mg. In other examples, saliva stimulators can be present in the composition in an amount from about 3 mg to about 5 mg, from about from about 1 mg to about 3 mg, from about 2.5 mg to about 5 mg, from about 2 mg to about 4 mg, or from about 1 mg to about 4 mg. In some specific examples, saliva stimulators can be present in an amount from about 2 mg to about 3 mg.
[0078] Compositions presented herein may also include a plasticizer. A non-limiting list of plasticizers which can be included in the composition can include vegetable glycerin, polyethylene glycol, dibutyl phthalate, or combinations thereof. Plasticizers can be present in the composition in an amount from about 0.5 wt% to about 5 wt% based on the total dry weight of the composition. In other examples, plasticizers can be present in the composition in an amount from about 1 wt% to about 5 wt%, from about 2 wt% to about 4 wt%, from about 0.5 wt% to about 2.5 wt%, or from about 1 wt% to about 3 wt% of the total dry weight of the composition. In some additional examples, plasticizers can be present in the composition in an amount from about 0.5 mg to about 5 mg. In other examples, plasticizers can be present in the composition in an amount from about 3 mg to about 5 mg, from about from about 1 mg to about 3 mg, from about 2.5 mg to about 5 mg, from about 0.5 mg to about 4 mg, or from about 1 mg to about 4 mg. In some specific examples, plasticizers can be present in an amount from about 1 mg to about 2 mg.
[0079] Compositions herein may also include a coloring agent. A non-limiting list of coloring agents which can be included in the composition can include red color, blue color, yellow color, green color, purple color, orange color, variants thereof, or combinations thereof. Coloring agents can be present in the composition in an amount from about 0.1 mg to about 3 mg. In other examples, coloring agents can be present in the composition in an amount from about 0.1 mg to about 1 mg, from about 0.5 mg to about 2 mg, from about 1 mg to about 3 mg, or from about 1.5 mg to about 2.5 mg. In some specific examples, the coloring agents can be present in an amount from about 0.5 mg to about 1.5 mg.
[0080] Compositions herein may also include a flavor modifier / agent. A non-limiting list of flavor modifiers / agent which can be included in the composition can include strawberry flavor extract, strawberry flavor extract, blueberry flavor concentrate, blueberry flavor extract, blackberry flavor extract, blackberry flavor concentrate, raspberry flavor extract, raspberry flavory concentrate, cranberry flavor extract, cranberry flavor concentrate, apple flavor extract, apple flavor concentrate, orange flavor extract, orange flavor concentrate, banana flavor extract, banana flavor concentrate, or combinations thereof. Flavor modifiers can be present in the composition in an amount from about 0.05 mg to about 10 mg. InThorpe North & Western, LLP
[0081] DocketNo.: 5016-005. PCT other examples, flavor modifiers can be present in the composition in an amount from about 0.05 mg to about 5 mg, from about 1 mg to about 6 mg, from about 2 mg to about 8 mg, from about 2 mg to about 10 mg, or from about 5 mg to about 10 mg. In some specific examples, flavor modifiers can be present in the composition in an amount from about 4 mg to about 5 mg.
[0082] Compositions herein may also include a thickening agent. A non-limiting list of thickening agents which can be included in the composition can include xanthan gum, acacia gum, alginate, bentonite, carbomer, calcium carbonate, calcium lactate, calcium phosphate, calcium silicate, calcium sulfate, carrageenan, cellulose, cetearyl alcohol, chitosan, dextran, dextrose, ethyl cellulose, fructose, gelatin, glyceryl, guar gum, hydroxyethylcellulose, magnesium aluminum silicate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, pectin, silica, sodium alginate, starch, poly silicone- 11, stearic acid, stearyl alcohol, talc, xylitol, or combinations thereof. Thickening agents can be present in the composition in an amount from about 0.1 wt% to about 2 wt% based on the total dry weight of the composition. In other examples, thickening agents can be present in the composition in an amount from about 0.1 wt% to about 1 wt%, from about 0.5 wt% to about 1 wt%, from about 0.5 wt% to about 2 wt%, or from about 1 wt% to about 2 wt% of the total dry weight of the composition. In some additional examples, thickening agents can be present in the composition in an amount from about 0.1 mg to about 2 mg. In other examples, thickening agents can be present in the composition in an amount from about 1 mg to about 2 mg, from about from about 0.1 mg to about 1 mg, from about 0.5 mg to about 1.5 mg, from about 0.5 mg to about 2 mg, or from about 1 mg to about 1.5 mg. In some specific examples, saliva stimulators can be present in an amount from about 0.5 mg to about 1 mg.
[0083] Compositions herein may also include an emulsifier. A non-limiting list of emulsifiers which can be included in the composition can include sunflower lecithin, polysorbates, carrageenan, sodium stearoyl lactylate, guar gum, mustard sed, agar, polyglycerol esters, cetostearyl alcohol, sucrose esters, sorbitan monostearate, acacia gum, sodium phosphates, pectin, polysorbate 80, or combinations thereof. Emulsifiers can be present in the composition in an amount from about 0.1 wt% to about 1 wt% based on the total dry weight of the composition. In other examples, emulsifiers can be present in the composition in an amount from about 0.1 wt% to about 0.2 wt%, from about 0.5 wt% to about 1 wt%, from about 0.5 wt% to about 0.75 wt%, or from about 0.1 wt% to about 0.5 wt% of the total dry weight of the composition. In some additional examples, emulsifiers can be present in theThorpe North & Western, LLP
[0084] DocketNo.: 5016-005. PCT composition in an amount from about 0.1 mg to about 1 mg. In other examples, emulsifiers can be present in the composition in an amount from about 0.1 mg to about 0.5 mg, from about from about 0.1 mg to about 0.75 mg, from about 0.5 mg to about 1 mg, from about 0.5 mg to about 0.75 mg, or from about 0.25 mg to about 0.75 mg.
[0085] Additionally, compositions herein may include a penetration enhancer. A nonlimiting list of penetration enhancers which can be included in the composition can include ethanol, isopropyl alcohol, propyl alcohol, propanol, alcohol decant, decanol, hexanol, lauryl alcohol, myristyl alcohol, octanol, octyl dodecanol, oleyl alcohol, laurocapram, ethyl acetate, octyl salicylate, padimate O. ethyl oleate, glyceryl monoleate, glyceryl monocaprate, glyceryl tricaprylate, isopropyl myristate, isopropyl palmitate, propylene glycol monolaurate, propylene glycol monocaprylate, diethylene glycol monoethyl ether, lauric acid, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitic acid, stearic acid, isosteric acid, dipropylene glycol, propylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, cyclodextrin, cell penetrating peptides (CPP), such as penetratin, or combinations thereof. Penetration enhancers can be present in the composition in an amount from about 0.01 mg to about 3 mg. In other examples, penetration enhancers can be present in an amount from about 0.01 mg to about 1 mg. from about 0.05 mg to about 2.5 mg, from about 1 mg to about 3 mg, or from about 1 mg to about 2.5 mg. In some specific examples, penetration enhancers can be present in an amount from about 0.05 mg to about 2 mg.
[0086] Furthermore, compositions herein can include a gumming agent. A non-limiting list of gumming agents which can be included in the composition include gum Arabic, xanthan gum, locust bean gum, agar, carrageenan, gellan gum, sodium alginate, tara gum, cornstarch, guar gum, gelatin, mastic gum, pectin, or combinations thereof. Gumming agents can be present in the composition in an amount from about 0.1 wt% to about 1 wt% based on the total dry weight of the composition. In other examples, gumming agents can be present in the composition in an amount from about 0.1 wt% to about 0.2 wt%, from about 0.5 wt% to about 1 wt%, from about 0.5 wt% to about 0.75 \vt%, or from about 0.1 wt% to about 0.5 wt% of the total dry’ weight of the composition. In some additional examples, gumming agents can be present in the composition in an amount from about 0.1 mg to about 1 mg. In other examples, gumming agents can be present in the composition in an amount from about 0.1 mg to about 0.5 mg, from about from about 0.1 mg to about 0.75 mg, from about 0.5 mg to about 1 mg, from about 0.5 mg to about 0.75 mg, or from about 0.25 mg to about 0.75 mg.
[0087] Thorpe North & Western, LLP
[0088] DocketNo.: 5016-005. PCT
[0089] In some examples, the compositions herein can also include a secondary active agent. The secondary active agent can be any compound, molecule, or material other than GHK-Cu that aids or increases in the therapeutic effectiveness of the compositions herein. Some non-limiting categories of secondary active agents can include peptides, hormones, or the like. A non-limiting list of secondary active agents that can be included in the composition includes oxytocin, aminophenylpyrolle, Bremelanotide (PT 141), tirzepatide, tetrasubstituted growth hormone-releasing factor (GRF) 1-29 (CJC 1295), Thymosin Alpha-1 (TAI), Body Protection Compound 157 (BPC-157), testosterone, progesterone, insulin, or combinations thereof. Generally, the secondary active agent can be present in the composition in an amount from about 0.01 mg to about 25 mg. In other examples, the secondary active agent can be present in the composition in an amount from about 0.01 mg to about 5 mg, from about 2 mg to about 10 mg, from about 5 mg to about 15 mg, or from about 2 mg to about 20 mg.
[0090] In some embodiments, it can be desirable or advantageous to pair GHK-Cu as the primary’ active agent with specific secondary agents in order to provide a target treatment effect. Examples of such combinations include without limitation the following as secondary active agents:
[0091] Peptide Primary Function How It Pairs or Compares with
[0092] GHK-Cu
[0093] Thymosin Beta-4 Tissue repair, Complements GHK-Cu by enhancing (TB-500) angiogenesis, antiwound healing and reducing inflammatory inflammation systemically
[0094] Matrixyl (Palmitoyl Collagen stimulation, Enhance anti-aging effects Pentapeptide-4) anti-wrinkle
[0095] Argireline (Acetyl Muscle relaxation, Targets expression lines; works well
[0096] Hexapeptide-8) wrinkle reduction with GHK-Cu for full-spectrum skin rejuvenation
[0097] Copper Tripeptides Similar to GHK-Cu Other tripeptide-copper complexes
[0098] (other than GHK) mimic GHK-Cu but may differ in delivery or stability
[0099] Thorpe North & Western, LLP
[0100] DocketNo.: 5016-005. PCT
[0101] IGF-1 (Insulin-like Cell proliferation, hair Works synergistically with GHK-Cu
[0102] Growth Factor 1) follicle stimulation in hair regrowth protocols; enhances follicle activity
[0103] Melanotan II Increases melanin Sometimes combined with GHK-Cu production in skin treatments to improve pigment evenness and sun protection
[0104] Epitalon Telomere support, While systemic, can be paired with longevity GHK-Cu for overall anti-aging therapies
[0105] Follistatin 344 Muscle growth, May block myostatin and help possible hair regrowth regenerate hair when used with topical peptides
[0106] Acetyl Tetrapeptide- Anti-DHT action, hair Combines well with GHK-Cu in
[0107] 3 (e.g., Capixyl®) anchoring topical hair loss serums for male pattern baldness
[0108] BPC-157 Gut and tissue May enhance total body regeneration healing, antiincluding hair and skin health inflammatory
[0109] Moreover, specific combinations of secondary agents with GHK-Cu can include without limitation:
[0110] Hair Growth Protocols: GHK-Cu + IGF-1 + Acetyl Tetrapeptide-3
[0111] Skin Rejuvenation: GHK-Cu + Matrixyl + Argireline
[0112] Post-Procedure Recovery: GHK-Cu + TB-500 + BPC-157
[0113] Anti-Aging Regimens: GHK-Cu + Epitalon (systemic), possibly with NAD+ support
[0114] In some embodiments of the composition, a wetting agent can be included. A nonlimiting list of wetting agents that can be included in the composition can include water, phosphate-buffered saline (PBS), Dulbecco’s PBS, Alsever’s solution. Tris-buffered saline (TBS), balanced salt solutions (BSS), such as Hank’s BSS, Earle’s BSS, Grey's BSS, Puck's BSS, Simm’s BSS, Tyrode’s BSS, BSS Plus, Ringer's lactate solution, normal saline (i.e. 0.9% saline), A normal saline, the like, or a combination thereof. The wettingThorpe North & Western, LLP
[0115] DocketNo.: 5016-005. PCT agent can be present in the composition in an amount from about 50% to about 80% of the total wet weight of the composition. In other examples, the wetting agent can be present in the composition in an amount from about 50% to about 70%, from about 55% to about 75%, from about 50% to about 65%, of from about 60% to about 80% of the total wet weight of the composition.
[0116] Additionally, at least one of the active agent or secondary active agent can be present in a micron-sized or less sized form, including nano-sized. As used herein, ^nanosized,” '‘nano-particle,” ‘'nano” and the like refer to the active agent and / or the secondary active agent having a size substantially within the nanometer range or below (e.g. below 100 nm). Incorporating and maintaining the active agent and / or secondary active agent in nano-sized form can permit the agent to move more easily past a body’s natural barriers and increase accessibility and therapeutic efficacy. For example, nano-sized particles can more readily pass into and through layers of the oral mucosa and enter systemic circulation.
[0117] It is to be understood that all ingredients, including active agents, secondary active agents, optional ingredients, and any other ingredients, can be in powdered form, liquid form, in the form of a solid polymer, or any form necessary to achieve the desired composition.
[0118] The present disclosure also describes methods of administering an active agent, which includes providing a composition as previously described and administering the composition to the oral cavity of a subject. The delivery route of drugs and supplements is an important aspect to consider in order to effectively administer an active agent to the desired site of action in the body. The oral delivery’ route, specifically enterally, is one of the most popular routes of delivery’ for administering compositions. However, it also faces many challenges when it comes to the goal of effectively administering the active agent to the desired site of action in the body. One of these challenges is that the composition must survive the highly acidic and active environment of the stomach. If the composition survives here, it must then survive the action of bile salts and intestinal enzy matic activity in the intestinal tract. Another challenge is that some compositions undergo significant hepatic metabolism on first pass, reducing bioavailability of the active agent. Yet further, some molecules are not readily absorbed through the small intestine epithelium for a number of reasons, including size limitations, etc.
[0119] Thus, the methods herein can include administering the composition transmucosally. Mucosal surfaces, such as the oral mucosa, are a convenient route for delivering compositions to the body being that they are highly vascularized and permeable,Thorpe North & Western, LLP
[0120] DocketNo.: 5016-005. PCT providing increased bioavailability and rapid onset of action. This is because the composition does not pass through the digestive system and thereby avoids first pass metabolism. In some examples, the composition can be administered sublingually, or under the tongue. In other examples, the composition can be administered buccally, or against the inside lining of the cheek, gum, or roof of the oral cavity. These highly permeable regions of the oral mucosa allow the composition to diffuse through the oral mucosa and have direct access to systemic circulation. This means that the majority of the active agent is diffused through the oral mucosa. In some examples, formulations of the present invention may be administered to the oral mucosa in a way such that less than 40% of the active agent escapes through the enteral route. In other examples, less than 35%, 25%, 15%, or 5% of the active agent escapes through the enteral route. In some specific examples, less than 2% of the active agent escapes through the enteral route. Some examples of handling or placing the formulation within the oral cavity in order to achieve the above-recited delivery may include minimizing or controlling the exposure of the formulation to saliva and / or controlling the rate at which the formulation dissolves within the oral cavity or otherwise releases the active agent.
[0121] The present disclosure additionally describes methods of treating a condition responsive to an active agent therapy in a subject. Non-limiting examples of the condition can include wounds, inflammatory conditions, cancer, cosmetic conditions, and the like. The methods can include administering a therapeutically effective amount of an active agent to a mucosal surface of the subject’s oral cavity with an orally-dissolvable carrier as described herein. As previously mentioned, in some examples of the methods, the composition can be administered transmucosally to the oral cavity. A non-limiting list of example locations of administration include the roof of the mouth, the tongue, under the tongue, the gum, the cheek, sublingual tissue, the like, or combinations thereof.
[0122] The methods can also include allowing the orally-dissolvable carrier to dissolve against the mucosal surface. In some examples, this can take some time for the orally-dissolvable carrier to dissolve and for the active agent to be released from the orally-dissolvable carrier. In some instances, this can take from about 5 seconds to 120 seconds. In other examples this can take from about 5 seconds to about 30 seconds, from about 10 seconds to about 45 seconds, from about 5 seconds to about 100 seconds, or from about 30 seconds to about 120 seconds.
[0123] In some examples, a method of providing therapy, including GHK-Cu therapy can include administering a therapeutically effective amount thereof in an oral strip formulationThorpe North & Western, LLP
[0124] DocketNo.: 5016-005. PCT as recited herein according to a regimen of about 5 days of administration, followed by 2 days without administration, repeated for 90 days. Following the 90-day administration period, a 1 -month non-administration period can be implemented. After the 1 -month nonadministration period, the 90-day administration period can again commence. This on and off cycle can then be repeated.
[0125] Furthermore, the present disclosure describes methods of manufacture of the compositions previously described herein. The methods can include inserting the active agent into the wetting agent, allowing for the active agent to dissolve and forming a solution. In some examples, the active agent can be in powdered form, in which case the methods can include confirming dissolution of the powdered particles of the active agent. The methods can further include inserting any ingredients in solid polymer form to the solution, allowing for dissolution. The methods can also include inserting any flavor modifier and or plasticizers present into the solution, allowing for dissolution.
[0126] The methods can then include blending the solution and adding vacuum pressure. In some examples, blending can be conducted using a homogenizer. Vacuum pressure can be added to pressurize the solution to a range of from about 0.01 Mpa to about 0.15 Mpa. In other examples, vacuum pressure can be added to pressurize the solution to a range of from about 0.01 Mpa to about 0.05 Mpa, from about 0.05 Mpa to about 0.1 Mpa, from about 0.02 Mpa to about 0.12 Mpa, or from about 0.05 Mpa to about 0.15 Mpa. The methods can also include confirming the solution is fully homogenized and fully deaerated.
[0127] The methods can then include slowly adding the homogenized and de-aerated solution to a film making machine. The film making machine can be set to produce film of a desired thickness, at a certain temperature and speed. In some examples, film can be produced at a thickness of from about 0.1mm to about 0.8mm.
[0128] In some embodiments, depending on the specific active agent, water-soluble ingredients, are mixed with water, with the active agents sometimes being included first followed by flavor ingredients. The water is then warmed or heated sufficiently to suspend or otherwise dissolve the ingredients (e.g. 40C to 45C). Next, hydrophobic or oil soluble ingredients are heated and homogenized with the aqueous portion at high speeds. The resulting mixture is then cast into films. Once produced, the film can be added to a packaging machine, where it is cut to a desired length. In some examples, the desired length can be from about 25 mm to about 50 mm. In other examples the desired length can beThorpe North & Western, LLP DocketNo.: 5016-005. PCT from about 25 mm to about 30 mm, from about 30 mm to about 45 mm, or from about 30 mm to about 45 mm. The composition can then be packaged.
[0129] Examples
[0130] Example 1 – GHK-CU Oral Film Composition Method of Manufacture
[0131] An orally dissolvable film is prepared by adding 0.25 mg of GHK-Cu into 150mg of purified water, followed by 1.2 mg of hydroxypropyl beta-cyclodextrin, creating a solution. GHK-Cu and hydroxypropyl beta-cyclodextrin is allowed to fully dissolve. Next, 5.2 mg of pullulan, 9.8 mg of hydroxypropyl methylcellulose 5 mg of stevia, 1.5 mg of citric acid, 0.1 mg of Penetratin, 0.8 mg of red color, 0.52 mg of xanthan gum, 0.25 mg of sunflower lecithin, and 0.82 mg of gum Arabic is put into the solution and allowed to fully dissolve. Finally, 2 mg of vegetable glycerin, 0.15 mg of strawberry’ flavor extract, and 4.1 mg of strawberry’ flavor concentrate is added to the solution and allowed to fully dissolve.
[0132] The solution is then blended using a homogenizer, and vacuum pressurized to 0.09 Mpa. This fully homogenizes and de-aerates the solution. The solution is slowly added to a film making machine, which produces film. The film is then added to a packaging machine, where the film is cut to 40 mm in length.
[0133] The film composition has the following ingredients:
[0134] Table 1:
[0135]
[0136] Thorpe North & Western, LLP
[0137] DocketNo.: 5016-005. PCT
[0138]
[0139] Example 2 – Alternative Mucoadhesive GHK-Cu Film Composition
[0140] A mucoadhesive orally dissolvable fdm is prepared to provide transmucosal delivery’ of GHK-Cu through the oral mucosa. The composition includes GHK-Cu as the active agent, hydroxypropyl beta-cyclodextrin as a solubilizing agent and penetration enhancer, polyvinyl alcohol and hydroxypropyl methylcellulose as film-forming agents, sodium alginate as a mucoadhesive film-forming polymer, glycerin as a plasticizer, citric acid as a saliva stimulator, xylitol and sucralose as sweeteners, polysorbate 80 as an emulsifier, and peppermint flavor as a flavor modifier.
[0141] In one example, the film has the following composition per unit dose:
[0142] Table 2:
[0143]
[0144] Thorpe North & Western, LLP
[0145] DocketNo.: 5016-005. PCT
[0146]
[0147] The GHK-Cu and hydroxypropyl beta-cyclodextrin are dissolved in purified water to form an aqueous active-agent solution. Separately, polyvinyl alcohol, hydroxypropyl methylcellulose, and sodium alginate are hydrated in purified water with mixing to form a polymeric film-forming dispersion. The active-agent solution is combined with the polymeric dispersion, followed by addition of glycerin, citric acid, xylitol, sucralose, polysorbate 80, and peppermint flavor. The resulting mixture ias homogenized and deaerated under reduced pressure.
[0148] The mixture is cast onto a release liner and dried at a temperature sufficiently low to avoid degradation of GHK-Cu, such as from about 35°C to about 45°C, until a flexible, self-supporting film is formed. The dried film is cut into individual dosage units sized for placement against an oral mucosal surface, including a sublingual or buccal surface.
[0149] In some examples, the resulting film dissolves or erodes within about 1 seconds to about 120 seconds after placement in the oral cavity. In further examples, the sodium alginate and hydroxypropyl methylcellulose provide increased residence time against the oral mucosa, thereby facilitating transmucosal absorption of GHK-Cu and reducing loss of the active agent through swallowing or enteral delivery.
[0150] Example 3 – Alternative GHK-Cu Oral Adhesive Strip Composition
[0151] An oral adhesive strip is prepared for transmucosal administration of GHK-Cu. The strip includes GHK-Cu as the active agent, maltodextrin and pectin as film-forming and mucoadhesive agents, hydroxypropyl cellulose as a stabilizing film-forming polymer, sorbitol as a plasticizer and mouthfeel (organoleptic) modifier, sodium citrate as a
[0152] Thorpe North & Western, LLP
[0153] DocketNo.: 5016-005. PCT buffering agent, monk fruit extract and ery thritol as sweeteners, medium-chain triglycerides as a dispersion aid, gum acacia as an emulsifying and gumming agent, natural berry flavor as a flavor modifier, and purified water as a processing solvent.
[0154] In one example, the film has the following composition per unit dose:
[0155] Table 3:
[0156]
[0157] In preparing the composition, GHK-Cu is added to purified water with sodium citrate and mixed to form an aqueous active-agent solution. Separately, maltodextrin, pectin, and hydroxypropyl cellulose are hydrated in purified water to form a film-forming polymer dispersion. The active-agent solution is combined with the polymer dispersion, followed by addition of sorbitol, erythritol, monk fruit extract, gum acacia, medium-chain triglycerides, and natural berry flavor.
[0158] The resulting mixture is blended until substantially uniform and then de-aerated under reduced pressure. The mixture is film cast onto a release liner and dried at aThorpe North & Western, LLP
[0159] DocketNo.: 5016-005. PCT temperature selected to reduce degradation of GHK-Cu, such as from about 30°C to about 45°C, until a flexible oral adhesive strip is formed. The dried strip is cut into individual dosage units configured for placement against an oral mucosal surface, including a buccal, gingival, palatal, or sublingual surface.
[0160] In some examples, the pectin and hydroxypropyl cellulose increase adhesion of the strip to the oral mucosa and provide a residence time sufficient to promote transmucosal delivery of GHK-Cu. In further examples, the strip dissolves or erodes within about 0.1 seconds to about 150 seconds following placement in the oral cavity.
[0161] Example 4 – High-Dose Pullulan-Based GHK-Cu Oral Adhesive Strip
[0162] A high-dose orally dissolvable adhesive strip is prepared for transmucosal delivery of GHK-Cu. The strip includes pullulan as a primary film-forming polymer, polyvinylpyrrolidone as a secondary film-forming and stabilizing polymer, sodium carboxymethyl cellulose as a mucoadhesive and viscosity -modifying polymer, trehalose as a peptide-stabilizing excipient, mannitol as a mouthfeel modifier and bulking agent, sodium phosphate as a buffering agent, polyethylene glycol 400 as a plasticizer, sucrose laurate as a surfactant and penetration-enhancing excipient, potassium sorbate as a preservative, natural vanilla flavor as a flavor modifier, and purified water as a processing solvent.
[0163] In this example, the batch is formulated to provide about 6 mg GHK-Cu per finished strip. GHK-Cu is added to approximately 5,000 mg of purified water containing the sodium phosphate buffer and trehalose. The mixture is stirred at about 20°C to about 25°C for about 10 minutes to about 20 minutes until the GHK-Cu is substantially dissolved. The pH of the active-agent solution is adjusted or maintained at about pH 6.2 to about pH 7.0.
[0164] In a separate vessel, pullulan is dispersed into approximately 10,000 mg of purified water under moderate agitation. The pullulan dispersion is mixed for about 20 minutes to about 40 minutes until substantially hydrated. Poly vinylpyrrolidone K30 and sodium carboxymethyl cellulose were then slowdy added to the hydrated pullulan dispersion while mixing to form a substantially uniform polymeric casting solution. The polymeric casting solution was maintained at about 25°C to about 40°C during hydration. Mannitol, potassium sorbate, sucrose laurate, polyethylene glycol 400, and natural vanilla flavor were then added to the polymeric casting solution. The remaining purified water was added as needed to adjust casting viscosity. The GHK-Cu active-agent solution wasThorpe North & Western, LLP
[0165] DocketNo.: 5016-005. PCT then added to the polymeric casting solution under low-shear mixing to reduce foaming and peptide degradation. The resulting mixture was mixed for about 10 minutes to about 30 minutes until substantially uniform.
[0166] The mixture is de-aerated under reduced pressure, such as from about -0.05 MPa to about -0.09 MPa, for about 5 minutes to about 20 minutes. The de-aerated casting solution is then cast onto a release liner at a wet thickness selected to provide a dried strip mass of about 100 mg per dosage unit. The cast film is dried at about 30°C to about 40°C for about 20 minutes to about 60 minutes, or until the residual water content is less than about 10 wt%, such as from about 2 wt% to about 8 wt%.
[0167] After drying, the film is trimmed and cut into individual oral adhesive strips. Each finished strip has a target dry weight of about 100 mg and contains about 6 mg of GHK-Cu.
[0168] The resulting finished oral adhesive strip has the following composition per dosage unit:
[0169] Table 4:
[0170]
[0171] Thorpe North & Western, LLP
[0172] DocketNo.: 5016-005. PCT
[0173]
[0174] During manufacture, most of the purified water is removed during drying and was therefore not present in the finished strip except as residual moisture. In some examples, the amount of GHK-Cu added to the manufacturing process is greater than the intended finished amount per strip to compensate for processing losses. For example, about 105 mg of GHK-Cu can be added to a batch intended to produce 100 strips each containing about 1.0 mg of GHK-Cu, thereby providing about a 5% manufacturing overage.
[0175] In some examples, the finished strip is configured to adhere to an oral mucosal surface and dissolve or erode within about 20 seconds to about 180 seconds after placement in the oral cavity'. The combination of pullulan, polyvinylpyrrolidone, and sodium carboxymethyl cellulose provides film strength, flexibility, and mucosal residence time, while trehalose and the phosphate buffer stabilize GHK-Cu during manufacture and storage.
[0176] Example Embodiments
[0177] The following examples pertain to specific technology embodiments and point out specific features, elements, or steps that may be used or otherwise combined in achieving such embodiments.
[0178] In one example there is provided a composition including an orally-dissolvable film having a therapeutically effective amount of Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu).
[0179] In one example of a composition, the GHK-Cu is present in an amount from about 1 wt% to about 28 wt% of the total dry weight of the composition.
[0180] In one example of a composition, the GHK-Cu is present in an amount of from about 0.75 mg to about 1.75 mg.
[0181] In one example of a composition, the composition further includes a wetting agent.
[0182] Thorpe North & Western, LLP
[0183] DocketNo.: 5016-005. PCT
[0184] In one example of a composition, the wetting agent is selected from at least one of water, phosphate-buffered saline (PBS), Dulbecco's PBS. Alsever’s solution. Trisbuffered saline (TBS), balanced salt solutions (BSS), such as Hank’s BSS, Earle’s BSS, Grey’s BSS, Puck’s BSS, Simm’s BSS, Tyrode’s BSS, BSS Plus, Ringer’s lactate solution, normal saline (i.e. 0.9% saline), ½ normal saline, or combinations thereof.
[0185] In one example of a composition, the wetting agent is present in an amount of from about 50 wt% to about 80 wt% of the total wet weight of the composition.
[0186] In one example of a composition, the composition further includes at least one of a fdm former, stabilizer, sweetener, saliva stimulator, plasticizer, coloring agent, flavor modifier, thickening agent, emulsifier, penetration enhancer, or gumming agent.
[0187] In one example of a composition, the film former comprises pullulan. sodium alginate, HPMC E3 or E5 or E15, CMC, polyvinylpyrollidone, pectin, gelatin, or combinations thereof.
[0188] In one example of a composition, the film former is present in an amount of from about 40 wt% to about 65 wt% of the total dry weight of the composition.
[0189] In one example of a composition, the film former is present in an amount of from about 45 mg to about 80 mg.
[0190] In one example of a composition the stabilizer comprises hydroxypropyl methylcellulose.
[0191] In one example of a composition, the stabilizer is present in an amount of from about 0.5 wt% to about 10 wt% of the total dry weight of the composition.
[0192] In one example of a composition, the stabilizer is present in an amount of from about 2 mg to about 15 mg.
[0193] In one example of a composition, the sweetener is selected from stevia, aspartame, sucralose, acesulfame potassium, saccharin, luo han guo, erythritol, xylitol, or a combination thereof.
[0194] In one example of a composition, the sweetener is present in an amount of from about 0.5 wt% to about 12 wt% of the total dry weight of the composition.
[0195] In one example of a composition, the sweetener is present in an amount of from about 3 mg to about 12 mg.
[0196] In one example of a composition, the saliva stimulator is selected from citric acid, malic acid, tartaric acid or combinations thereof.
[0197] In one example of a composition, the saliva stimulator is present in an amount of from about 0.5 wt% to about 5 wt% of the total dry weight of the composition.
[0198] Thorpe North & Western, LLP
[0199] DocketNo.: 5016-005. PCT
[0200] In one example of a composition, the saliva stimulator is present in an amount of from about 1 mg to about 5 mg.
[0201] In one example of a composition, the plasticizer comprises vegetable glycerin.
[0202] In one example of a composition, the plasticizer is present in an amount of from about 0.5 wt% to about 5 wt% of the total dry weight of the composition.
[0203] In one example of a composition, the plasticizer is present in an amount of from about 0.5 mg to about 5 mg.
[0204] In one example of a composition, the coloring agent is selected from red color, blue color, yellow color, or combinations thereof.
[0205] In one example of a composition, the coloring agent is present in an amount of from about 0.1 mg to about 3 mg.
[0206] In one example of a composition, the flavor modifier is selected from strawberry flavor extract, strawberry' flavor extract, blueberry' flavor concentrate, blueberry flavor extract, blackberry flavor extract, blackberry' flavor concentrate, raspberry' flavor extract, raspberry flavory concentrate, cranberry flavor extract, cranberry flavor concentrate, apple flavor extract, apple flavor concentrate, orange flavor extract, orange flavor concentrate, banana flavor extract, banana flavor concentrate, or combinations thereof.
[0207] In one example of a composition, the flavor modifier is present in an amount of from about 0.05 mg to about 10 mg.
[0208] In one example of a composition, the composition further includes hydroxypropyl beta cyclodextrin.
[0209] In one example of a composition, the hydroxypropyl beta cyclodextrin is present in an amount of from about 1 wt% to about 35 wt% of the total dry weight of the composition.
[0210] In one example of a composition, the hydroxypropyl beta cyclodextrin is present in an amount of from about 0.5 mg to about 1.5 mg.
[0211] In one example of a composition, the thickening agent is selected from xanthan gum, acacia gum, alginate, bentonite, carbomer, calcium carbonate, calcium lactate, calcium phosphate, calcium silicate, calcium sulfate, carrageenan, cellulose, cetearyl alcohol, chitosan, dextran, dextrose, ethyl cellulose, fructose, gelatin, glycery l, guar gum, hydroxy ethylcellulose, magnesium aluminum silicate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, pectin, silica, sodium alginate, starch, polysilicone-11, stearic acid, stearyl alcohol, talc, xylitol, or combinations thereof.
[0212] Thorpe North & Western, LLP
[0213] DocketNo.: 5016-005. PCT
[0214] In one example of a composition, the thickening agent is present in an amount of from about 0.1 wt% to about 2 wt% of the total dry weight of the composition.
[0215] In one example of a composition, the thickening agent is present in an amount of from about 0.1 mg to about 2 mg.
[0216] In one example of a composition, the emulsifier is selected from sunflower lecithin, polysorbates, carrageenan, sodium stearoyl lactylate, guar gum, mustard sed, agar, polyglycerol esters, cetostearyl alcohol, sucrose esters, sorbitan monostearate, acacia gum, sodium phosphates, pectin, polysorbate 80, or combinations thereof.
[0217] In one example of a composition, the emulsifier is present in an amount of from about 0.1 wt% to about 1 wt% of the total dry weight of the composition.
[0218] In one example of a composition, the emulsifier is present in an amount of from about 0.1 mg to about 1 mg.
[0219] In one example of a composition, the penetration enhancer is selected from ethanol, isopropyl alcohol, propyl alcohol, propanol, alcohol decant, decanol, hexanol, lauryl alcohol, myristyl alcohol, octanol, octyl dodecanol. oleyl alcohol, laurocapram, ethyl acetate, octyl salicylate, padimate O, ethyl oleate, glyceryl monoleate, glyceryl monocaprate, glyceryl tricaptylate, isopropyl myristate, isopropyl palmitate, propylene glycol monolaurate, propylene glycol monocaprylate, diethylene glycol monoethyl ether, lauric acid, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitic acid, stearic acid, isosteric acid, dipropylene glycol, propylene glycol. 1.2-butylene glycol, 1,3-butylene glycol, cyclodextrin, Penetratin, or combinations thereof.
[0220] In one example of a composition, the penetration enhancer is present in an amount of from about 0.01 mg to about 3 mg.
[0221] In one example of a composition, the gumming agent is selected from gum Arabic, xanthan gum, locust bean gum, agar, carrageenan, gellan gum, sodium alginate, tara gum, cornstarch, guar gum, gelatin, mastic gum, pectin, or combinations thereof.
[0222] In one example of a composition, the gumming agent is present in an amount of from about 0.1 wt% to about 1 wt% of the total dry weight of the composition.
[0223] In one example of a composition, the gumming agent is present in an amount of from about 0.1 mg to about 1 mg.
[0224] In one example there is provided a method of treating a condition responsive to Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu) therapy in a subject, including administering a therapeutically effective amount of GHK-Cu to a mucosal surface of theThorpe North & Western, LLP DocketNo.: 5016-005. PCT subject’s oral cavity with an orally-dissolvable film as recited in any of the previous examples and allowing the orally-dissolvable film to dissolve against the mucosal surface.
[0225] In one example of a method, the condition includes at least one of a wound, inflammatory conditions, cancer, cosmetic conditions, or combinations thereof.
[0226] In one example of a method, the mucosal surface of the subject's oral cavity includes at least one of a roof of a mouth, tongue, gum, cheek, or combinations thereof.
[0227] In one example of a method, all of the GHK-Cu is released from the orally-dissolvable film within about 5 seconds to about 120 seconds.
[0228] While the forgoing examples are illustrative of the specific embodiments in one or more particular applications, it will be apparent to those of ordinary skill in the art that numerous modifications in form, usage and details of implementation can be made without departing from the principles and concepts articulated herein.
[0229] In one example there is provided a method of administering Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu) including providing a composition as recited in any of the previous examples and administering the composition to the oral cavity of a subject.
[0230] In one example of a method, the administration of the composition is sublingual or buccal.
[0231] In one example of a method, the composition is administered to the roof of a mouth, the tongue, under the tongue, the gum, the cheek, or combinations thereof.
[0232] In one example of a method, less than 25% of the GHK-Cu escapes through the enteral route.
Claims
Thorpe North & Western, LLPDocketNo.: 5016-005. PCTCLAIMSWhat is claimed is:
1. A composition comprising:an orally-dissolvable film having a therapeutically effective amount of Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu).
2. The composition of claim 1, wherein GHK-Cu is present in an amount from about 1 wt% to about 28 wt% of the total dry weight of the composition.
3. The composition of claim 1, wherein GHK-Cu is present in an amount of from about 0.75 mg to about 1.75 mg.
4. The composition of claim 1, further comprising a wetting agent.
5. The composition of claim 4, wherein the wetting agent is selected from at least one of water, phosphate-buffered saline (PBS), Dulbecco’s PBS, Alsever’s solution, Trisbuffered saline (TBS), balanced salt solutions (BSS), such as Hank's BSS, Earle's BSS, Grey's BSS, Puck's BSS, Simm’s BSS, Tyrode's BSS, BSS Plus. Ringer’s lactate solution, normal saline (i.e. 0.9% saline), ½ normal saline.
6. The composition of claim 5, wherein the wetting agent is present in an amount of from about 50 wt% to about 80 wt% of the total wet weight of the composition.
7. The composition of claim 1, further comprising at least one of a film former, stabilizer, sweetener, saliva stimulator, plasticizer, coloring agent, flavor modifier, thickening agent, emulsifier, penetration enhancer, or gumming agent.
8. The composition of claim 7, wherein the film former is selected from pullulan, sodium alginate, HPMC E3 or E5 or El 5, CMC, polyvinylpyrollidone, pectin, gelatin, or combinations thereof.
9. The composition of claim 7, wherein the film former is present in an amount of from about 40 wt% to about 65 wt% of the total dry weight of the composition.Thorpe North & Western, LLPDocketNo.: 5016-005. PCT10. The composition of claim 7, wherein the film former is present in an amount of from about 45 mg to about 80 mg.
11. The composition of claim 1, further comprising hydroxypropyl beta cyclodextrin.
12. The composition of claim 11, wherein the hydroxypropyl beta cyclodextrin is present in an amount of from about 1 wt% to about 30 wt% of the total dry weight of the composition.
13. The composition of claim 11, wherein the hydroxypropyl beta cyclodextrin is present in an amount of from about 0.5 mg to about 1.5 mg.
14. The composition of claim 7, wherein the sweetener is selected from stevia, aspartame, sucralose, acesulfame potassium, saccharin, luo han guo, erythritol, xylitol, or a combination thereof.
15. The composition of claim 7, wherein the sweetener is present in an amount of from about 0.5 wt% to about 12 wt% of the total dry weight of the composition.
16. The composition of claim 7, wherein the sweetener is present in an amount of from about 3 mg to about 12 mg.
17. The composition of claim 7, wherein the saliva stimulator is selected from citric acid, malic acid, tartaric acid or combinations thereof.
18. The composition of claim 7, wherein the saliva stimulator is present in an amount of from about 0.5 wt% to about 5 wt% of the total dry weight of the composition.
19. The composition of claim 7, wherein the saliva stimulator is present in an amount of from about 1 mg to about 5 mg.
20. The composition of claim 7, wherein the plasticizer comprises vegetable glycerin.Thorpe North & Western, LLP DocketNo.: 5016-005. PCT21. The composition of claim 7, wherein the plasticizer is present in an amount of from about 0.5 wt% to about 5 wt% of the total dry weight of the composition.
22. The composition of claim 7, wherein the plasticizer is present in an amount of from about 0.5 mg to about 5 mg.
23. The composition of claim 7, wherein the coloring agent is selected from red color, blue color, yellow color, or combinations thereof.
24. The composition of claim 7, wherein the coloring agent is present in an amount of from about 0.1 mg to about 3 mg.
25. The composition of claim 7, wherein the flavor modifier is selected from strawberry flavor extract, strawberry flavor extract, blueberry flavor concentrate, blueberry flavor extract, blackberry flavor extract, blackberry flavor concentrate, raspberry flavor extract, raspberry flavory concentrate, cranberry flavor extract, cranberry flavor concentrate, apple flavor extract, apple flavor concentrate, orange flavor extract, orange flavor concentrate, banana flavor extract, banana flavor concentrate, or combinations thereof.
26. The composition of claim 7, wherein the flavor modifier is present in an amount of from about 0.05 mg to about 10 mg.
27. The composition of claim 7, wherein the stabilizer comprises hydroxypropyl methylcellulose.
28. The composition of claim 7, wherein the stabilizer is present in an amount of from about 0.5 wt% to about 10 wt% of the total dr ’ weight of the composition.
29. The composition of claim 7, wherein the stabilizer is present in an amount of from about 2 mg to about 15 mg.
30. The composition of claim 7, wherein the thickening agent is selected from xanthan gum, acacia gum, alginate, bentonite, carbomer, calcium carbonate, calciumThorpe North & Western, LLP DocketNo.: 5016-005. PCT lactate, calcium phosphate, calcium silicate, calcium sulfate, carrageenan, cellulose, cetearyl alcohol, chitosan, dextran, dextrose, ethyl cellulose, fructose, gelatin, glyceryl, guar gum, hydroxyethylcellulose, magnesium aluminum silicate, magnesium carbonate, magnesium oxide, maltodextrin, maltose, pectin, silica, sodium alginate, starch, polysilicone-11, stearic acid, stearyl alcohol, talc, xylitol, or combinations thereof.
31. The composition of claim 7, wherein the thickening agent is present in an amount of from about 0.1 wt% to about 2 wt% of the total dry weight of the composition.
32. The composition of claim 7, wherein the thickening agent is present in an amount of from about 0.1 mg to about 2 mg.
33. The composition of claim 7, wherein the emulsifier is selected from sunflower lecithin, polysorbates, carrageenan, sodium stearoyl lactylate, guar gum, mustard sed, agar, polyglycerol esters, cetostearyl alcohol, sucrose esters, sorbitan monostearate, acacia gum, sodium phosphates, pectin, polysorbate 80, or combinations thereof.
34. The composition of claim 7, wherein the emulsifier is present in an amount of from about 0.1 wt% to about 1 wt% of the total dry weight of the composition.
35. The composition of claim 7, wherein the emulsifier is present in an amount of from about 0.1 mg to about 1 mg.
36. The composition of claim 7, wherein the penetration enhancer is selected from ethanol, isopropyl alcohol, propyl alcohol, propanol, alcohol decant, decanol, hexanol, lauryl alcohol, myristyl alcohol, octanol, octyl dodecanol, oleyl alcohol, laurocapram, ethyl acetate, octyl salicylate, padimate O, ethyl oleate, glyceryl monoleate, glyceryl monocaprale, glyceryl tricaprylate, isopropyl myristate, isopropyl palmitate, propylene glycol monolaurate, propylene glycol monocaprylate, diethylene glycol monoethyl ether, lauric acid, linoleic acid, linolenic acid, myristic acid, oleic acid, palmitic acid, stearic acid, isosteric acid, dipropylene glycol, propylene glycol, 1,2-butylene glycol, 1,3- butylene glycol, cyclodextrin, Penetratin, or combinations thereof.Thorpe North & Western, LLPDocketNo.: 5016-005. PCT37. The composition of claim 7, wherein the penetration enhancer is present in an amount of from about 0.01 mg to about 3 mg.
38. The composition of claim 7, wherein the gumming agent is selected from gum Arabic, xanthan gum, locust bean gum, agar, carrageenan, gellan gum, sodium alginate, tara gum. cornstarch, guar gum, gelatin, mastic gum, pectin, or combinations thereof.
39. The composition of claim 7, wherein the gumming agent is present in an amount of from about 0.1 wt% to about 1 wt% of the total dry weight of the composition.
40. The composition of claim 7, wherein the gumming agent is present in an amount of from about 0.1 mg to about 1 mg.
41. A method of treating a condition responsive to Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu). therapy in a subject, comprising:administering a therapeutically effective amount of GHK-Cu to a mucosal surface of the subject’s oral cavity with an orally-dissolvable film as recited in any of claims 1-40; andallowing the orally-dissolvable film to dissolve against the mucosal surface.
42. The method of claim 41, wherein the condition includes at least one of a wound, inflammatory conditions, cancer, cosmetic conditions, or combinations thereof.
43. The method of claim 41, wherein the mucosal surface of the subject’s oral cavity includes at least one of a roof of a mouth, tongue, gum, cheek, or combinations thereof.
44. The method of claim 41, wherein all of the GHK-Cu is released from the orally-dissolvable film within about 5 seconds to about 120 seconds.
45. A method of administering Glycyl-L-Histidyl-L-Lysine Copper (GHK-Cu). comprising:providing a composition as recited in any of claims 1-40; and administering the composition to the oral cavity of a subject.Thorpe North & Western, LLPDocketNo.: 5016-005. PCT46. The method of claim 45, wherein the administration of the composition is sublingual or buccal.
47. The method of claim 45, wherein the composition is administered to the roof of a mouth, the tongue, under the tongue, the gum, the cheek, or combinations thereof.
48. The method of claim 45, wherein less than 25% of the GHK-Cu escapes through the enteral route.
